Latest Neoadjuvant Therapy Stories
Enables physicians and patients to proactively avoid toxicities from treatments unlikely to provide benefit SAN FRANCISCO, Jan.16, 2014 /PRNewswire/ -- Castle Biosciences today announced
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14.
In research published this week in PLoS Medicine, JÃ¶rg Kleeff from Technische UniversitÃ¤t MÃ¼nchen, and colleagues suggest that patients with apparently locally non-resectable tumors should be included in neoadjuvant protocols.
- A political dynamiter.